WO2010061680A1 - Cathéter - Google Patents

Cathéter Download PDF

Info

Publication number
WO2010061680A1
WO2010061680A1 PCT/JP2009/065749 JP2009065749W WO2010061680A1 WO 2010061680 A1 WO2010061680 A1 WO 2010061680A1 JP 2009065749 W JP2009065749 W JP 2009065749W WO 2010061680 A1 WO2010061680 A1 WO 2010061680A1
Authority
WO
WIPO (PCT)
Prior art keywords
catheter according
medicine
supporter
catheter
flow
Prior art date
Application number
PCT/JP2009/065749
Other languages
English (en)
Japanese (ja)
Inventor
香由 木村
正伸 清原
Original Assignee
オリンパス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2008305500A external-priority patent/JP2010125227A/ja
Priority claimed from JP2008305499A external-priority patent/JP2010125226A/ja
Priority claimed from JP2008305501A external-priority patent/JP2010125228A/ja
Application filed by オリンパス株式会社 filed Critical オリンパス株式会社
Publication of WO2010061680A1 publication Critical patent/WO2010061680A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/0069—Tip not integral with tube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02—Holding devices, e.g. on the body
    • A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters

Definitions

  • the present invention relates to a catheter attached to a body organ of a mammal including human beings, and more particularly to a catheter for administering a drug from the surface of the body organ to the body organ.
  • Patent Document 1 a catheter that administers a drug by inserting a puncture needle into a body organ of a mammal including a human is known (see Patent Document 1).
  • the conventional catheter basically administers the drug only to one point inside the internal organ, even if it is desired to administer the drug to the affected area having a certain volume, the part of the affected part separated from the administration position I wasn't able to spread the drug very much.
  • the depth of the puncture needle may be insufficient and the puncture needle may come off. In such a case, sufficient drug administration is performed. I could't.
  • the drug is administered by sticking a sheet or gel soaked with the drug on the surface of the internal organ (see Patent Document 2).
  • the present invention has been made in view of the above, and an object of the present invention is to provide a catheter capable of easily and reliably administering a drug to a predetermined region near the surface of a body organ.
  • a catheter according to the present invention is a catheter attached to a body organ of a mammal including a human, and a conduit for guiding a drug from a drug supply source into the body;
  • the total area of the one or more openings is wider than the cross-sectional area of the internal passage.
  • the pad is a flexible sheet portion, and the one or more openings are provided on the back surface of the pad.
  • the back surface of the sheet portion is formed with a close contact area that is in close contact with the surface of the internal organ and a non-adhesion area that is not in close contact with the surface of the internal organ.
  • the plurality of openings are provided in the non-contact region.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the surface of the close contact area is formed smoothly, and the surface of the non-contact area is formed rougher than the close contact area.
  • the catheter according to the present invention is the above-described invention, wherein the one or more openings are not positioned separately from the non-contact area where the one or more openings are positioned on the back surface of the sheet portion.
  • a flow path connecting the region is formed.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the flow path is a groove formed on a back surface of the sheet portion.
  • the flow path is a groove formed on the back surface of the sheet portion by forming a protrusion on the back surface side of the sheet portion by bubbles formed inside the sheet portion. It is characterized by that.
  • the catheter according to the present invention is characterized in that, in the above-described invention, the flow path is a lumen formed in the seat portion.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the flow path is a lumen formed inside the seat portion, and the inside of the lumen is porous.
  • the catheter according to the present invention further includes a spacer disposed between the back surface of the sheet portion and the surface of the internal organ, and the spacer is formed on the side wall and the sheet portion side.
  • An upper opening and a lower opening formed on the internal organ side, and at least a surface of the internal organ covered by the lower opening serves as the non-contact region.
  • the catheter according to the present invention includes a connection member that connects the conduit and the seat portion, and the conduit and the seat portion are detachably coupled by the connection member. It is characterized by that.
  • the catheter according to the present invention is characterized in that, in the above invention, the back surface of the sheet portion is in close contact with the surface of the internal organ by intermolecular force.
  • the seat portion is connected to the conduit on the conduit side, and has a cross-sectional area wider than the cross-sectional area of the internal passage of the conduit, It has the connection part which forms the empty room which contact
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the seat portion is provided with an air vent valve.
  • the catheter according to the present invention is characterized in that, in the above invention, the sheet portion is formed of a member having air permeability.
  • the pad is a flexible supporter part that winds around the internal organs and has a supporter function, and the one or more openings are on the back surface of the pad. It is provided in.
  • the supporter portion has a plurality of connection bands, and the position is fixed with respect to the internal organ surface by surrounding the internal organs with the connection bands. It is characterized by.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, a hook is provided at a distal end portion of the connection band.
  • a cord is provided at a distal end portion of the connection band, and adjustment of tightening of the cord to adjust fixation of the supporter portion to the internal organ. It is characterized by.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the supporter part includes an adjustment part for adjusting the adhesion strength to the internal organ.
  • the catheter according to the present invention is characterized in that, in the above invention, the adjusting section is a plurality of balloons arranged in a distributed manner.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the adjustment portion is a plurality of openings formed in a dispersed manner.
  • the back surface of the supporter portion is formed with a close contact area that is in close contact with the surface of the internal organ and a non-adhesion area that is not in close contact with the surface of the internal organ.
  • the plurality of openings are provided in the non-contact region.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the surface of the close contact area is formed smoothly, and the surface of the non-contact area is formed rougher than the close contact area.
  • the catheter according to the present invention is the above-described invention, wherein the one or more openings are not located on the back surface of the supporter part, apart from the non-contact area where the one or more openings are located.
  • a flow path connecting the region is formed.
  • the catheter according to the present invention is characterized in that, in the above invention, the flow path is a groove formed on a back surface of the supporter portion.
  • the flow path is a groove formed on the back surface of the sheet portion by forming a protrusion on the back surface side of the sheet portion by bubbles formed inside the supporter portion. It is characterized by that.
  • the catheter according to the present invention is characterized in that, in the above invention, the flow path is a lumen formed inside the supporter portion.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the flow path is a lumen formed inside the supporter portion, and the inside of the lumen has a porous shape.
  • the catheter according to the present invention further includes a spacer disposed between the back surface of the supporter portion and the surface of the internal organ, and the spacer is formed on the side wall and the supporter side.
  • An upper opening and a lower opening formed on the internal organ side, and at least a surface of the internal organ covered by the lower opening serves as the non-contact region.
  • the catheter according to the present invention includes a connection member that connects the conduit and the supporter portion, and the conduit and the supporter portion are detachably coupled by the connection member. It is characterized by that.
  • the catheter according to the present invention is characterized in that, in the above invention, the back surface of the supporter is in close contact with the surface of the internal organ by intermolecular force.
  • the catheter according to the present invention is the catheter according to the above invention, wherein the supporter portion is connected to the duct on the duct side and has a cross-sectional area wider than the cross-sectional area of the internal passage of the duct, It has the connection part which forms the empty room which contact
  • the catheter according to the present invention is characterized in that, in the above invention, the supporter part is provided with an air vent valve.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the supporter part is formed of a member having air permeability.
  • the pad is prohibited or permitted from one state in which the pad receives energy transmitted from the outside of the pad and permits or prohibits the flow of the drug in the pad. And a gate mechanism for transitioning to the other state.
  • the energy is energy that propagates into the catheter via the catheter surface.
  • the state transition of the gate mechanism is caused by the energy that has entered from the catheter surface around the gate mechanism.
  • Such energy is, for example, wave energy irradiated from the outside.
  • wave energy is energy that travels in the form of waves, including but not limited to sound waves, ultrasonic waves, electromagnetic waves (including radio waves, infrared rays, visible light, ultraviolet rays), shock waves, and mechanical vibrations. Pulses are also included in the wave. Application of such energy causes destruction, deformation (melting, expansion, etc.) of the members of the gate mechanism, and as a result, a transition state of the gate mechanism occurs.
  • the gate mechanism has a member to be destroyed that is destroyed by the irradiation of the wave energy, and the state is changed by the destruction of the member to be destroyed. It is characterized by.
  • the member to be destroyed is a member that prohibits the flow of the medicine
  • the gate mechanism receives the irradiation of the wave energy and destroys the member to be destroyed.
  • the medicine flow is changed from a state in which the medicine flow is prohibited to a state in which the medicine is allowed to flow.
  • the member to be destroyed is a member that allows the flow of the medicine, and is biased in a direction to move to a position that prohibits the flow of the medicine
  • the gate mechanism has an urging member that is prevented from moving by a breaking member, and the gate mechanism inhibits the urging member from flowing the drug by receiving the wave energy and destroying the member to be broken. It is moved to a position to make a transition from a state in which the medicine flow is allowed to a state in which it is prohibited.
  • the catheter according to the present invention is characterized in that, in the above invention, the member to be destroyed is ceramic.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the gate mechanism has a deformable member that is deformed by receiving the energy, and the state is changed by deformation of the deformable member.
  • the gate mechanism makes a transition from a state in which the flow of the medicine is prohibited to a state in which the flow of the medicine is permitted by receiving the energy and deforming the deformable member.
  • the deformation member is a member that allows the flow of the medicine, and is biased in a direction to move to a position that prohibits the flow of the medicine, and the deformation member And the gate mechanism moves the urging member to a position where the flow of the medicine is prohibited by the deformation of the deforming member upon receiving the energy. It is characterized by making a transition from a state in which the flow is allowed to a state in which it is prohibited.
  • the deformable member is a thermoplastic plastic.
  • the wave energy is a combination of one or more of an electromagnetic wave including a sound wave, an ultrasonic wave, an infrared ray and visible light, including a high frequency, a shock wave, and a mechanical vibration. It is characterized by energy.
  • the catheter according to the present invention is characterized in that, in the above invention, the wave energy is energy output from a laser device.
  • the wave energy is energy output from an ultrasonic transducer.
  • the wave energy is energy output from a shock wave generator.
  • the catheter according to the present invention is the above-described invention, wherein the pad has a drug discharge unit for discharging the drug in the pad, the drug discharge unit and the gate mechanism are plural, and at least one drug
  • the ejection unit is characterized in that the gate mechanism makes a transition between an active state in which the medicine is ejected and an inactive state in which the medicine is not ejected.
  • the gate mechanism is provided inside the sheet-like pad.
  • the catheter according to the present invention is characterized in that, in the above invention, the pad has an osmotic membrane, and the drug is discharged into the body through the osmotic membrane.
  • the catheter according to the present invention is characterized in that, in the above-mentioned invention, the pad has an opening, and the drug is discharged into the body through the opening.
  • a puncture needle is provided at a distal end of the conduit, and the drug is discharged into the body through the puncture needle, and the gate mechanism is connected to the conduit. It is provided in the middle.
  • the conduit has a branch portion that branches from one passage on the drug supply side to a plurality of passages, and the gate mechanism is connected to the branch portion.
  • a plurality of at least one passage branched from the branching portion performs a state transition between an active state in which a drug is caused to flow through the passage and an inactive state in which the agent is not caused to flow through the passage by the gate mechanism.
  • the catheter according to the present invention is characterized in that, in the above invention, the branch portion is a mesh-like passage.
  • the pad forms one or more openings that communicate with the internal passage of the duct, and the total area of the one or more openings is Since it is made wider than the cross-sectional area of the internal passage, it is possible to easily and reliably administer the drug to a predetermined region near the surface of the internal organ.
  • FIG. 1 is a schematic diagram showing a state where the catheter according to the first embodiment of the present invention is applied to a human body.
  • FIG. 2 is a schematic view showing an installation state of the catheter shown in FIG. 1 in the vicinity of the internal organ.
  • FIG. 3 is a plan view showing an installed state of the catheter shown in FIG. 1 in the vicinity of the internal organ.
  • FIG. 4 is a cross-sectional view showing a configuration of a modified example of the catheter shown in FIG.
  • FIG. 5 is a plan view showing a modification of the sheet portion of the catheter shown in FIG.
  • FIG. 1 is a schematic diagram showing a state where the catheter according to the first embodiment of the present invention is applied to a human body.
  • FIG. 2 is a schematic view showing an installation state of the catheter shown in FIG. 1 in the vicinity
  • FIG. 8 is a cross-sectional view showing a configuration of a modified example of the flow path of the catheter shown in FIG.
  • FIG. 9 is a cross-sectional view showing a configuration of a modification of the flow path of the catheter shown in FIG.
  • FIG. 10 is a cross-sectional view illustrating a configuration of a modified example of the flow path of the catheter illustrated in FIG. 6.
  • FIG. 11 is a schematic diagram showing an installation mode of the catheter according to the second embodiment of the present invention.
  • FIG. 12 is a schematic diagram showing a configuration of a modified example of the spacer of the catheter according to the second embodiment of the present invention.
  • FIG. 13 is a schematic diagram showing a configuration of a modification of the catheter spacer according to the second embodiment of the present invention.
  • FIG. 14 is a schematic diagram showing a state in which the catheter according to the third embodiment of the present invention is applied to a human body.
  • FIG. 15 is a schematic diagram showing an installation state of the catheter shown in FIG. 14 in the vicinity of the internal organ.
  • FIG. 16 is a plan view showing an installation state of the catheter shown in FIG. 14 in the vicinity of the internal organ.
  • FIG. 17 is a cross-sectional view showing a configuration of a modified example of the catheter shown in FIG.
  • FIG. 18 is a perspective view showing a modification of the supporter unit shown in FIG.
  • FIG. 19 is a perspective view showing a modification of the supporter unit shown in FIG.
  • FIG. 20 is a perspective view showing a modification in which a plurality of balloons are provided on the supporter unit shown in FIG.
  • FIG. 21 is a cross-sectional view showing a deformed state of the balloon shown in FIG.
  • FIG. 22 is a perspective view showing a modified example in which a plurality of openings are formed in the supporter part shown in FIG.
  • FIG. 23 is a plan view showing a modification of the supporter portion of the catheter shown in FIG.
  • FIG. 26 is a cross-sectional view showing a configuration of a modification of the flow path of the catheter shown in FIG.
  • FIG. 27 is a cross-sectional view showing a configuration of a modified example of the flow path of the catheter shown in FIG. FIG.
  • FIG. 28 is a cross-sectional view showing a configuration of a modification of the flow path of the catheter shown in FIG.
  • FIG. 29 is a schematic diagram showing an installation mode of the catheter according to the fourth embodiment of the present invention.
  • FIG. 30 is a schematic diagram showing a configuration of a modified example of the spacer of the catheter according to the fourth embodiment of the present invention.
  • FIG. 31 is a schematic diagram showing a configuration of a modification of the catheter spacer according to the fourth embodiment of the present invention.
  • FIG. 32 is a schematic diagram illustrating a state in which the catheter according to the fifth embodiment of the present invention is applied to a human body.
  • FIG. 33 is a view of the drug discharge portion of the catheter shown in FIG. 32 as seen from the back side.
  • FIG. 33 is a view of the drug discharge portion of the catheter shown in FIG. 32 as seen from the back side.
  • FIG. 34 is an exploded perspective view showing the configuration of the medicine discharge section of the catheter shown in FIG.
  • FIG. 35 is a perspective view showing the configuration of the second gate mechanism.
  • FIG. 36 is a perspective view showing the configuration of the first gate mechanism.
  • FIG. 37 is a schematic diagram showing the operation of the first gate mechanism.
  • FIG. 38 is a schematic diagram showing an example of a mechanism for supplying energy to the gate mechanism from the outside via the surface of the catheter.
  • FIG. 39 is a schematic diagram showing an example of a mechanism for supplying energy to the gate mechanism from the outside via the surface of the catheter.
  • FIG. 40 is a schematic view of Modification 1 of the medicine ejection unit viewed from the back side.
  • FIG. 41 is a schematic diagram of Modification 2 of the medicine ejection unit viewed from the back side.
  • FIG. 42 is a perspective view showing a configuration of Modification Example 3 of the catheter.
  • FIG. 43 is an exploded perspective view showing the configuration of the gate mechanism of Modification 4 of Embodiment 5 of the present invention.
  • FIG. 44 is a diagram illustrating the operation of the gate mechanism shown in FIG.
  • FIG. 1 is a schematic diagram showing a state where the catheter according to the first embodiment of the present invention is applied to a human body.
  • FIG. 2 is a schematic diagram showing an installed state of the catheter shown in FIG. 1 in the vicinity of the internal organ.
  • FIG. 3 is a plan view showing an installation state of the catheter shown in FIG. FIG. 1 shows a case where, for example, about several tens ml of anticancer drug or the like is continuously and intensively discharged over a long period of about one week on the surface of a body organ 4 such as the liver for planned administration.
  • medical agent here contains a liquid and a gel-form chemical
  • the catheter 10 has a tube (pipe) 2 and a sheet portion 1.
  • the tube 2 is connected to a drug injection device 3 attached to the body surface 6, and the sheet portion 1 corresponding to the pad of the present invention is in close contact with the surface of the internal organ 4 supported by the organ supporting tissue 5 in the body. It is fixed to the internal organ 4.
  • the drug injection device 3 is a device that plans and administers several tens of ml of drug to the surface of the internal organ 4 continuously and intensively over a long period of about one week.
  • the medicine accumulated in the medicine reservoir is pushed out in a minute amount by an electroosmotic flow pump or the like and administered through the catheter 10.
  • the medicine feeding device 3 into the body through the tube 2, and the medicine diffuses from the opening 12 provided on the back surface of the sheet portion 1 to a predetermined range on the back surface side of the sheet portion 1. And absorbed by the internal organ 4 from its surface.
  • medical agent injection apparatus 3 does not need to be attached to the body surface 6,
  • positioned apart from the body are possible.
  • the sheet portion 1 is a sheet-like material made of a flexible biocompatible material, such as a PVDC (polyvinylidene chloride) film, a polyethylene film, or silicon rubber.
  • the tube 2 extends from the surface of the sheet portion 1 and is formed of a flexible biocompatible material such as polyethylene.
  • an opening 12 communicating with the internal passage of the tube 2 is formed on the back surface of the sheet portion 1.
  • a connecting portion 11 is provided on the sheet portion 1 side of the tube 2, and an empty chamber 23 surrounded by the connecting portion 11 and the organ surface 8 of the internal organ 4 is formed.
  • the opening 12 below the vacant chamber 23 is in contact with the region E2 of the organ surface 8 that is the surface of the internal organ 4 in an area wider than the cross-sectional area of the internal passage of the tube 2.
  • the back surface of the peripheral portion excluding the connecting portion 11 of the sheet portion 1 is formed smoothly, forms a close contact region 21, and is in close contact with the region E 1 of the body organ 4.
  • the mucous membrane 9 on the surface of the internal organ 4 promotes close contact with the close contact region 21.
  • the back surface of the connection part 11 is made into the rough surface, for example, it is preferable that it is a porous material, for example, and it becomes easy to form the empty room 23 by this.
  • the upper part of the opening 12 becomes a non-contact region 22 that does not adhere to the organ surface 8, and a vacancy 23 is formed, and the periphery of the vacancy 23 adheres closely to the organ surface 8. It becomes area 21.
  • the medicine 7 introduced from the medicine feeding device 3 through the tube 2 flows into the vacant chamber 23 formed inside the connecting portion 11.
  • the drug 7 that has flowed into the vacant chamber 23 penetrates and fills the vacant chamber 23 and is absorbed into the internal organ 4 from the region E2 (opening 12) in contact with the organ surface 8.
  • the medicine 7 is administered from the region E2 (opening 12) of the organ surface 8 having an area larger than the cross section of the internal passage of the tube 2, and the catheter 10 is closely fixed to the body organ 4, the comparison is made. Stable drug administration can be easily performed over a long period of time.
  • the adhesion region 21 is, for example, a polymer composition in which 10 to 100 parts by weight of a hydrogenated diene block copolymer is blended with 100 parts by weight of an epoxidized diene block copolymer. You may make it use a thing.
  • the close contact between the sheet portion 1 and the internal organ 4 is not limited to intermolecular force, and may be realized by applying gel at the close contact portion, adhering with sutures, fibrin glue or the like.
  • the tube 2 and the seat portion 1 can be detachably attached by connecting portions 30a and 30b (30) realized by a fluid socket or a fluid outlet provided at each end portion. It may be.
  • an air vent valve 31 for venting the air in the empty chamber 23 may be provided in the connecting portion 11.
  • the air vent valve 31 is provided with a filter through which air can pass to the outside but no medicine or the like can pass.
  • the air remaining in the vacant chamber 23 is pressed by the inflow of the drug 7, but the internal air is released to the outside by the air vent valve 31, so that the drug can be reliably administered. it can.
  • the material of the seat part 1 or the connecting part 11 may be formed of a breathable material through which only air can pass.
  • the non-contact region 22 is a closed region surrounded by the contact region 21, but not limited thereto, as shown in FIG.
  • An opening region 22 a that communicates with the outside may be provided in a part of the region 22.
  • the medicine 7 that has flowed into the vacant room 23a corresponding to the vacant room 23 is not in a pressurized state in the vacant room 23a, and the medicine 7 can be smoothly introduced through the tube 2 by releasing the pressure. .
  • the amount of the drug 7 to be introduced is very small, and by adjusting the dose corresponding to the absorption of the drug into the body organ 4, it is possible to prevent the drug from being greatly administered beyond the non-contact region 22. .
  • the medicine 7 may spread beyond the non-contact region 22.
  • the non-contact regions 22b and 22c may be formed in different regions in the sheet portion 1 to provide the vacancies 23b and 23c.
  • the opening 12 on the tube 2 side is disposed in one non-contact area 22b, and a flow path 32 communicating with each other is provided between the non-contact areas 22b and 22c.
  • the flow path 32 is realized, for example, by setting a flow path forming region 33 on the back surface of the sheet portion 1 as a material having a rough surface, as shown in FIG.
  • This flow path forming region 33 is in a state of floating from the organ surface 8, and the flow path 32 is formed.
  • bubbles 35 are formed inside the sheet portion 1 in the flow path forming region, and at least the back side of the sheet portion 1 is a convex portion, and the sheet portion 1 on the side surface of the convex portion is separated from the organ surface 8.
  • the space between the sheet portion 1 and the organ surface 8 may be separated and used as the flow path 32.
  • the formation of the bubbles 35 can be realized by making a cut corresponding to the flow path forming region inside the sheet portion 1 and injecting air into the cut. This break can be realized by forming a laminate.
  • a foaming agent that reacts with light or heat is injected into the flow path forming region inside the sheet portion 1 and is expanded by irradiating the foaming agent with light or heat to form bubbles. It may be.
  • a lumen that is a communication hole 36 may be formed in the flow path forming region in the sheet portion 1 to form the flow path 32.
  • the flow path 32 may be formed by filling the lumen with a porous material 37.
  • the porous material 37 is realized by, for example, a bundle of hollow fibers (hollow fibers) having an inner diameter of about 100 ⁇ m used for artificial kidneys and the like. This hollow fiber is realized by regenerated cellulose (such as cuprophan or acetyl cellulose), polymethyl methacrylate, polyvinyl alcohol ethylene copolymer, polysulfone, or the like.
  • the sheet portion 1 having a material such as vinyl chloride in part may be focused on ultraviolet rays along the target lumen shape to destroy the crosslinked structure of vinyl chloride, thereby forming a porous structure.
  • a spacer is further provided between the seat portion 1 and the internal organ 4 so that an empty chamber corresponding to the empty chamber 23 can be reliably formed.
  • FIG. 11 is a schematic diagram showing an installation mode of the catheter according to the second embodiment of the present invention.
  • a spacer 40 covered with the sheet part 1 is provided between the sheet part 1 and the internal organ 4.
  • This spacer 40 is for reliably forming the empty chamber 23 shown in FIG. 3, and includes a side wall 42 and a flange 41 formed on the side of the body organ 4 at the periphery of the side wall 42.
  • the side wall 42 is formed so as to surround the empty room 45 corresponding to the empty room 23.
  • the cylinder formed by the side wall 42 is formed with an upper opening 43 on the seat portion 1 side and a lower opening 44 on the body organ 4 side.
  • the upper opening 43 covers the sheet portion 1.
  • the opening on the tube 2 side of the sheet portion 1 to which the tube 2 is coupled is covered with the upper opening 43.
  • the back surface of the flange 41 has a smooth surface like the contact area 21, and is in close contact with the organ surface 8 of the internal organ 4 to fix the spacer 40.
  • the spacer 40 secures the vacant chamber 45 having a predetermined volume, and the vacant chamber 45 as a closed space is further ensured by the contact region 21 at the periphery of the seat portion 1.
  • the opening 12 of the sheet portion 1 is substantially the opening 12 a below the spacer 40.
  • the spacer 50 which can form the non-contact
  • the sheet portion 1 is covered so that the opening on the tube 2 side is located in the upper opening 53.
  • seat part 1 does not cover the side surface opening 55, you may cover it.
  • the spacer 50 forms an empty space by the upper surface on the sheet portion 1 side having the upper opening 53, the lower opening 54 formed on the body organ 4 side, the side wall 52, and the side surface opening 55.
  • a spacer 60 capable of forming the non-contact region 22 and the vacant spaces 23b and 23c corresponding to FIG. 6 may be used.
  • the sheet portion 1 is covered so that the opening on the tube 2 side is located in the upper opening 64.
  • the side walls 62 and 63 and the flange 61 are provided, and further the lower openings 65 and 67 are formed, and the space between the empty chambers 69b and 69c is formed.
  • a bridge portion 68 for connection is provided.
  • the bridge portion 68 may or may not be formed with a flow path that communicates between the vacancies 69b and 69c. Further, when the flow path is provided, the upper opening 66 may be blocked.
  • the spacers 40, 50, 60 are closely fixed to the internal organ 4 by the back surfaces of the flanges 41, 51, 61.
  • the present invention is not limited to this, and stitching, adhesion, etc.
  • the spacers 40, 50, 60 may be fixed to the internal organ 4.
  • Embodiments 1 and 2 since a sheet-like sheet portion is used as a pad, a drug can be administered over a wide range on the organ surface with a simple configuration.
  • FIG. 14 is a schematic diagram showing a state in which the catheter according to the third embodiment of the present invention is applied to a human body.
  • FIG. 15 is a schematic diagram showing an installation state of the catheter shown in FIG. 14 in the vicinity of the internal organ.
  • FIG. 16 is a plan view showing an installed state of the catheter shown in FIG. 14 in the vicinity of the internal organ.
  • FIG. 14 shows, for example, a case where a drug such as an anticancer drug of about several tens ml is continuously and intensively discharged over a long period of about one week on the surface of a body organ 4 such as the liver for planned administration.
  • medical agent here contains a liquid and a gel-form chemical
  • the catheter 10 has a tube 2 and a supporter 101.
  • the tube 2 is connected to the drug injection device 3 attached to the body surface 6, and the supporter unit 101 corresponding to the pad of the present invention surrounds the surface of the internal organ 4 supported in the body by the organ supporting tissue 5, The position is fixed with respect to the organ 4 surface.
  • the drug injection device 3 is a device that plans and administers several tens of ml of drug to the surface of the internal organ 4 continuously and intensively over a long period of about one week.
  • the medicine accumulated in the medicine reservoir is pushed out in a minute amount by an electroosmotic flow pump or the like and administered through the catheter 10.
  • a prescribed amount of medicine is introduced from the medicine injection device 3 into the body through the tube 2, and the medicine diffuses from the opening 12 provided on the back surface of the supporter unit 101 to a predetermined range on the backside of the supporter unit 101. And absorbed by the internal organ 4 from its surface.
  • medical agent injection apparatus 3 does not need to be attached to the body surface 6,
  • positioned apart from the body are possible.
  • the supporter unit 101 is formed of a sheet-like, flexible biocompatible material, such as a PVDC (polyvinylidene chloride) film, a polyethylene film, or silicon rubber.
  • the tube 2 extends from the surface of the supporter 101 and is formed of a flexible biocompatible material such as polyethylene.
  • an opening 12 communicating with the internal passage of the tube 2 is formed on the back surface of the supporter 101.
  • a connecting part 11 is provided on the supporter 101 side of the tube 2, and an empty chamber 23 surrounded by the connecting part 11 and the organ surface 8 of the internal organ 4 is formed.
  • the opening 12 below the vacant chamber 23 is in contact with the region E2 of the organ surface 8 that is the surface of the internal organ 4 in an area wider than the cross-sectional area of the internal passage of the tube 2.
  • the supporter part 101 has at least a part of the surface in contact with the body organ 4 on the back surface formed in a smooth manner, and is in close contact with the body organ 4 by intermolecular force.
  • the back surface of the peripheral portion excluding the connecting portion 11 of the supporter portion 101 is formed smoothly, forms a close contact region 21, and is in close contact with the region E 1 of the internal organ 4.
  • the mucous membrane 9 on the surface of the internal organ 4 promotes close contact with the close contact region 21.
  • the back surface of the connection part 11 is made into the rough surface, for example, it is preferable that it is a porous material, for example, and it becomes easy to form the empty room 23 by this.
  • the upper portion of the opening 12 becomes a non-contact area 22 that does not adhere to the organ surface 8, and a vacancy 23 is formed, and the periphery of the vacancy 23 adheres closely to the organ surface 8. It becomes area 21.
  • the medicine 7 introduced from the medicine feeding device 3 through the tube 2 flows into the vacant chamber 23 formed inside the connecting portion 11.
  • the drug 7 that has flowed into the vacant chamber 23 penetrates and fills the vacant chamber 23 and is absorbed into the internal organ 4 from the region E2 (opening 12) in contact with the organ surface 8.
  • the medicine 7 is administered from the region E2 (opening 12) of the organ surface 8 having an area larger than the cross section of the internal passage of the tube 2, and the catheter 10 is closely fixed to the body organ 4, the comparison is made. Stable drug administration can be easily performed over a long period of time.
  • the adhesion region 21 is, for example, a polymer composition in which 10 to 100 parts by weight of a hydrogenated diene block copolymer is blended with 100 parts by weight of an epoxidized diene block copolymer. You may make it use a thing.
  • the close contact between the supporter 101 and the internal organ 4 is not limited to the intermolecular force, and may be realized by applying gel at the close contact portion, adhering by suturing, fibrin glue or the like.
  • connection between the tube 2 and the supporter 101 is made detachable by connecting portions 30a and 30b (30) realized by a fluid socket or a fluid outlet provided at each end. It may be.
  • an air vent valve 31 for venting the air in the empty chamber 23 may be provided in the connecting portion 11.
  • the air vent valve 31 is provided with a filter through which air can pass to the outside but no medicine or the like can pass.
  • the air remaining in the vacant chamber 23 is pressed by the inflow of the drug 7, but the internal air is released to the outside by the air vent valve 31, so that the drug can be reliably administered. it can.
  • the supporter 101 or the connecting part 11 may be made of a breathable material through which only air can pass.
  • the supporter unit 101 shown in FIG. 14 surrounds the surface of the internal organ 4 by fitting the internal organ 4 into the internal organ 4 from one end of the internal organ 4, but as shown in FIG. It is preferable to provide the connecting bands 101a to 101e.
  • a male and female hook 111 is provided at the corresponding distal end of each of the connecting bands 101a to 101e, and the position of the internal organ 4 is fixed by the hook 111 after the surface of the internal organ 4 is covered. In this case, even if the organ supporting tissue 5 is present, the position of the supporter 101 can be easily fixed with respect to the internal organ 4.
  • the position of the supporter 101 may be fixed with respect to the internal organ 4 by connecting the distal ends of the connecting bands 101a to 101e to each other using the cord 112.
  • the cord 112 includes a string, a thread, a wire, and the like.
  • the balloons 103 distributed in the supporter unit 101 may be formed.
  • the balloon 103 is filled with a fluid 104 such as air or physiological saline, and the presence of the balloon 103 can increase the fixing strength of the supporter 101 to the internal organ 4. it can.
  • the fixation strength is adjusted by puncturing the desired balloon 103 with a puncture needle 105 or the like to break the balloon 103 and causing the fluid 104 in the balloon 103 to flow out.
  • the fixing strength can be reduced.
  • the balloon 103 may be newly formed by blowing fluid with the puncture needle 105 or the like and closing the puncture portion.
  • the fixing strength is adjusted by providing openings 106 dispersedly arranged in the supporter part 101 and forming a cut part 107 by making a cut between the adjacent openings 106. It may be.
  • the non-contact region 22 is a closed region surrounded by the contact region 21, but not limited to this, as shown in FIG.
  • An opening region 22 a that communicates with the outside may be provided in a part of the region 22.
  • the medicine 7 that has flowed into the vacant room 23a corresponding to the vacant room 23 is not in a pressurized state in the vacant room 23a, and the medicine 7 can be smoothly introduced through the tube 2 by releasing the pressure. .
  • the amount of the drug 7 to be introduced is very small, and by adjusting the dose corresponding to the absorption of the drug into the body organ 4, it is possible to prevent the drug from being greatly administered beyond the non-contact region 22. .
  • the medicine 7 may spread beyond the non-contact region 22.
  • the non-contact regions 22b and 22c may be formed in different regions in the supporter 101 to provide the vacancies 23b and 23c.
  • the opening 12 on the tube 2 side is disposed in one non-contact area 22b, and a flow path 32 communicating with each other is provided between the non-contact areas 22b and 22c.
  • the flow path 32 is realized by setting a flow path forming region 33 on the back surface of the supporter 101 as a material having a rough surface. This flow path forming region 33 is in a state of floating from the organ surface 8, and the flow path 32 is formed.
  • bubbles 35 are formed inside the supporter part 101 in the flow path forming region, and at least the back side of the supporter part 101 is a convex part, and the supporter part 101 on the side surface of the convex part is separated from the organ surface 8.
  • the space between the supporter 101 and the organ surface 8 may be separated and used as the flow path 32.
  • the formation of the bubbles 35 can be realized by making a cut corresponding to the flow path forming region inside the supporter 101 and injecting air into the cut. This break can be realized by forming a laminate.
  • a foaming agent that foams in response to light or heat is injected into the flow path forming region inside the supporter 101, and the foaming agent is expanded by irradiating light or heat to form bubbles. It may be.
  • a lumen that is a communication hole 36 may be formed in the flow path forming region in the supporter 101 to form the flow path 32.
  • the lumen 32 may be filled with a porous material 37 to form the flow path 32.
  • the porous material 37 is realized by, for example, a bundle of hollow fibers (hollow fibers) having an inner diameter of about 100 ⁇ m used for artificial kidneys and the like. This hollow fiber is realized by regenerated cellulose (such as cuprophan or acetyl cellulose), polymethyl methacrylate, polyvinyl alcohol ethylene copolymer, polysulfone, or the like.
  • the supporter 101 having a part of a material such as vinyl chloride may focus on ultraviolet rays along a target lumen shape to destroy the crosslinked structure of vinyl chloride, thereby forming a porous structure.
  • a spacer is further provided between the supporter 101 and the internal organ 4 so that a vacancy corresponding to the vacancy 23 can be reliably formed.
  • FIG. 29 is a schematic diagram showing an installation mode of the catheter according to the fourth embodiment of the present invention.
  • a spacer 40 covered with the supporter unit 101 is provided between the supporter unit 101 and the internal organ 4.
  • This spacer 40 is for reliably forming the empty space 23 shown in FIG. 16, and has a side wall 42 and a flange 41 formed on the side of the body organ 4 at the periphery of the side wall 42.
  • the side wall 42 is formed so as to surround the empty room 45 corresponding to the empty room 23.
  • An upper opening 43 on the supporter 101 side and a lower opening 44 on the body organ 4 side are formed in the cylinder formed by the side wall 42.
  • the upper opening 43 covers the supporter part 101.
  • the opening on the tube 2 side of the supporter part 101 to which the tube 2 is coupled is covered with the upper opening 43.
  • the back surface of the flange 41 has a smooth surface like the contact area 21, and is in close contact with the organ surface 8 of the internal organ 4 to fix the spacer 40.
  • the spacer 40 ensures a vacant chamber 45 having a predetermined volume, and the vacant chamber 45 as a closed space is further ensured by the contact region 21 at the periphery of the supporter 101.
  • the opening 12 of the supporter portion 101 is substantially the opening 12 a below the spacer 40.
  • the vacant chamber 45 can be reliably ensured, and the medicine administration region can be reliably widened through the opening 12a.
  • the instability of the region boundary in which a part of the non-contact region 22 changes to the contact region 21 or a part of the contact region 21 changes to the non-contact region 22 with time is reduced, and stable.
  • the necessary non-contact area 22 can be secured.
  • the spacer 50 which can form the non-contact
  • the supporter 101 is covered so that the opening on the tube 2 side is located in the upper opening 53. Further, the supporter unit 101 preferably does not cover the side opening 55, but may cover it.
  • the spacer 50 forms an empty space by the upper surface on the supporter 101 side having the upper opening 53, the lower opening 54 formed on the body organ 4 side, the side wall 52, and the side surface opening 55.
  • the supporter unit 101 is covered such that the opening on the tube 2 side is located in the upper opening 64.
  • the side walls 62 and 63 and the flange 61 are provided, and further the lower openings 65 and 67 are formed, and the space between the empty chambers 69b and 69c is formed.
  • a bridge portion 68 for connection is provided.
  • the bridge portion 68 may or may not be formed with a flow path that communicates between the vacancies 69b and 69c. Further, when the flow path is provided, the upper opening 66 may be blocked.
  • the spacers 40, 50, 60 are tightly fixed to the internal organ 4 by the back surfaces of the flanges 41, 51, 61.
  • the present invention is not limited to this, and stitching, adhesion, etc.
  • the spacers 40, 50, 60 may be fixed to the internal organ 4.
  • the support portion functioning as a supporter for winding the body organ is used as the pad, it is possible to stably and reliably administer the drug to the organ surface.
  • FIG. 32 is a schematic diagram illustrating a state in which the catheter according to the fifth embodiment of the present invention is applied to a human body.
  • FIG. 33 is a view of the drug discharge portion of the catheter shown in FIG. 32 as viewed from the internal organ side.
  • FIG. 34 is an exploded perspective view of the medicine discharge section of the catheter shown in FIG. FIG. 32 shows a case where, for example, a planned dosing is performed by continuously and intensively discharging a drug such as an anticancer drug of about several tens of ml to the surface of a body organ 4 such as the liver over a long period of about one week.
  • medical agent here contains a liquid and a gel-form chemical
  • the catheter 10 includes a tube 2 that is a drug passage and a sheet-like drug discharge unit 201.
  • the tube 2 is connected to the medicine injection device 3 attached to the body surface 6 and is connected to the medicine ejection unit 201 via the connector 216a.
  • the drug discharge unit 201 corresponds to the pad of the present invention, is in close contact with the surface of the internal organ 4 supported in the body by the organ support tissue 5, and is fixed to the internal organ 4.
  • the drug to be supplied is penetrated into the body organ 4 surface.
  • the drug injection device 3 is a device that plans and administers several tens of ml of drug to the surface of the internal organ 4 continuously and intensively over a long period of about one week.
  • the medicine accumulated in the medicine reservoir is pushed out in a minute amount by an electroosmotic flow pump or the like and administered through the catheter 10. That is, a prescribed amount of medicine is introduced from the medicine injection device 3 into the body through the tube 2, and the medicine diffuses from the back surface of the medicine ejection section 201 to a predetermined range to be selected, and the surface of the body organ 4 Is absorbed from.
  • medical agent injection apparatus 3 does not need to be attached to the body surface 6, For example, the structure embedded in a body and the structure arrange
  • the medicine ejection unit 201 has a three-layer structure including an upper layer 213, an intermediate layer 214, and a lower layer 215, and is bonded to each other.
  • the intermediate layer 214 is sandwiched between the upper layer 213 and the lower layer 215 and is made of a flexible biocompatible material such as silicon rubber, and is preferably a thick layer of 0.5 mm to 5 mm.
  • the upper layer 213 is made of a flexible biocompatible material, such as polyethylene, and is thinner than the intermediate layer 214, preferably a layer having a thickness of 0.05 mm to 0.3 mm.
  • the lower layer 215 is made of, for example, polysulfone, and is a flexible and biocompatible material that allows a drug to permeate.
  • the lower layer 215 is thinner than the intermediate layer 214, and preferably has a thickness of 0.05 mm to 0.3 mm.
  • the upper layer 213 has a protruding portion 217 from which the thin film is drawn to the tube 2 side.
  • a connector 216b is provided at the tip of the projecting portion 217, and is connected to the tube 2 by connecting the connector 216a and the connector 216b. That is, the connection between the connectors 216a and 216b allows the opening at the tip of the protrusion 217 to communicate with the internal passage of the tube 2.
  • a first opening 207, a second opening 208, and a flow path 209 communicating between the first opening 207 and the second opening 208 are formed inside the intermediate layer 214.
  • a protrusion 217 is disposed in the opening region of the first opening 207.
  • the first gate mechanism 211 that permits the flow of the drug in the initial state and prohibits the flow of the drug by receiving energy from the outside, and prohibits the flow of the drug in the initial state
  • a second gate mechanism 212 that accepts the energy of the medicine and permits the flow of the medicine. Note that only one of the first gate mechanism 211 and the second gate mechanism 212 may be provided. For convenience of explanation, in FIGS. 33 and 34, the first gate mechanism 211 and the second gate mechanism 212 are provided. A configuration in which both of the mechanisms 212 are arranged in the flow path 209 is shown.
  • the lower layer 215 may be a thin film in which only regions corresponding to the first opening 207 and the second opening 208 are opened, instead of the permeable membrane through which only the drug permeates.
  • the medicine supplied from the medicine injection device 3 is introduced into the protruding portion 217 of the upper layer 213 of the medicine ejection section 201 via the tube 2 and the connectors 216a and 216b, and further introduced into the first opening 207 of the intermediate layer 214. .
  • the drug introduced into the first opening 207 passes through the region of the lower layer 215 corresponding to the first opening 207 and permeates into the body from the surface of the internal organ 4.
  • the first gate mechanism 211 permits the flow of the medicine in the initial state, the medicine travels through the flow path 209 from the first opening 207 toward the second opening 208 side. Therefore, the second gate mechanism 212 that inhibits the flow of the drug prevents the flow of the drug, and the drug is not introduced into the second opening 208.
  • the medicine is supplied only to the surface of the internal organ 4 corresponding to the first opening 207.
  • the drug is supplied to the surface of the internal organ 4 from the corresponding region between the first opening 207 and the second gate mechanism 212 on the flow path 209, but is a linear region. The drug supply is negligible.
  • the flow path 209 includes the first opening 207 and the second flow path 209.
  • the medicine is supplied to the first opening 207 via the flow path 209, and the region of the lower layer 215 corresponding to the second opening 208 is communicated with the opening 208. It penetrates and is supplied to the surface of the internal organ 4. That is, the second opening 208 transitions from an inactive state in which medicine ejection is prohibited to an active state in which medicine is ejected. In this case, the medicine is also supplied from the surface of the internal organ 4 corresponding to the first opening 207.
  • the flow path 209 includes the first opening 207 and the second opening 208.
  • the drug supplied to the first opening 207 is supplied from the region of the lower layer 215 corresponding to the first opening 207 to the surface of the body organ 4 only. That is, the second opening 208 transitions from an active state in which the medicine is discharged to an inactive state in which the discharge of the medicine is prohibited. In this way, as a result, the dynamic change of the positional distribution of the drug amount can be easily performed.
  • the second gate mechanism 212 is a silica-alumina that breaks into a pair of recesses 219 provided facing the side surface of the flow path 209 by an ultrasonic shock wave or the like from the outside.
  • a cylindrical pellet 218 formed of ceramics realized by calcium phosphate ceramics is inserted. The pellet 218 closes the flow path 209 by being inserted into the recess 219 and locked to the flow path 209.
  • the pellet 218 is a member to be destroyed that is destroyed when receiving energy through the surface of the catheter 10 from the outside. Therefore, when the pellet 218 is destroyed, the second gate mechanism 212 allows the drug flow from a state in which the drug flow is prohibited.
  • the first gate mechanism 211 is formed with a recess 223 that locks the columnar pellet 220 on one side of the flow path 209 and at the recess 223.
  • a space 224 that is a recess for accommodating the elastic piece 225 is formed on the opposite side portion.
  • the elastic piece 225 is realized by a metal such as steel having a biocompatible coating, for example, and one end is cantilevered in the vicinity of the space 224 on the side of the flow path 209 in which the space 224 is formed. The other end is pressed by the pellet 220 and stored in the space 224.
  • the pellet 220 is formed with a communication hole 221 having an opening 222 penetrating from one side surface to the other side surface, and the pellet 220 is inserted into the flow channel 209 so that the communication direction of the communication hole 221 matches the flow direction of the flow channel 209. And locked.
  • the elastic piece 225 blocks the flow path 209 with its own elastic force and inhibits the flow of the drug when the pellet 220 is not present.
  • the first gate mechanism 211 is in a state where the elastic piece 225 presses the pellet 220 toward the concave portion 223 while the pellet 220 is locked to the flow path 209. It is installed to become.
  • the elastic piece 225 is an urging member that is urged by its own elastic force so as to move to a position where the flow path 209 is blocked and the flow of the medicine is prohibited. Therefore, instead of the elastic piece 225, a biasing member that biases by an extension spring or the like may be used.
  • the pellet 220 is formed of a member to be destroyed realized by ceramics or the like that breaks when receiving energy through the surface of the catheter 10.
  • the flow of the medicine is allowed.
  • the elastic piece 225 becomes elastic as shown in FIG. 37 (b). It moves to a position where the flow path 209 is closed by force, and closes the flow path 209.
  • the pellets 218 and 220 are not limited to ceramics, and may be realized with various materials such as glass and plastic in relation to energy supplied from the outside.
  • various wave energies such as sound waves, ultrasonic waves, electromagnetic waves including infrared rays and visible light, shock waves, and mechanical vibrations can be used.
  • it may be thermal energy transmitted by conduction. Heat can also be transmitted as wave energy by infrared rays.
  • pellets 218 and 220 may be deformable members that are deformed by external energy.
  • it may be a thermoplastic plastic that is deformed by thermal energy.
  • the pellet 218 may be formed by a balloon having a fluid such as air inside.
  • This balloon may be realized by bubbles.
  • a reversible gate mechanism that opens and closes the flow path 209 by expanding and contracting the fluid in the balloon without destroying the balloon may be used.
  • FIG. 38 is a schematic diagram illustrating a state in which wave energy such as a sound wave, an ultrasonic wave, and a shock wave is applied from outside the body.
  • the wave energy generator 231 generates wave energy based on the signal supplied from the driver 232 via the signal line 233.
  • the wave energy is collected by the wave lens 230 provided on the side of the gate mechanisms 218 and 220 of the wave energy generator 231 and is irradiated to the gate mechanisms 218 and 220.
  • the wave energy generation device 231 is realized by an ultrasonic transducer, a shock wave generation device, a sound wave source, or the like.
  • the energy generation unit of the energy generation device 235 is inserted into the body through the internal channel of the rigid endoscope 234, the energy generation unit is positioned in the vicinity of the gate mechanisms 218 and 220, and the energy generation unit to the gate mechanism 218. , 220 is supplied with energy.
  • the energy generation device 235 generates energy from the energy generation unit based on a signal supplied from the driver 240 via the signal line 241.
  • the energy for example, laser light by holmium / YAG laser, ultrasonic wave, high frequency, mechanical vibration, or the like is used. Of course, it may be heat transmitted by conduction.
  • FIG. 40 is a view of a medicine ejection unit 250, which is Modification 1 of the medicine ejection unit 201, as viewed from the back side.
  • the medicine ejection unit 201 has one second opening 208, but the medicine ejection unit 250 has a plurality of second openings 252.
  • the first opening 251 corresponding to the first opening 207 and the four second openings 252 are provided in a radial pattern, and each of the four flow paths is provided between the first opening 251 and the second opening 252.
  • a channel 209 is provided, and each channel 209 is provided with a first gate mechanism 211 and a second gate mechanism 212, respectively, similarly to the medicine ejection unit 201.
  • the lower layer 215 is not an osmotic membrane, but has an opening only in a region corresponding to the first opening 251 and the second opening 252.
  • the medicine in the initial state, the medicine is supplied only in the region corresponding to the first opening 261.
  • the drug supply distribution can be dynamically changed in detail.
  • a gate mechanism 212 may be appropriately combined, or a gate mechanism that performs reversible opening and closing may be used.
  • the gate mechanism is not limited to the node and may be provided on the flow path 209.
  • the flow path 209 is formed between the first opening and the second opening.
  • the first opening or the second opening is formed in an empty area of the flow path 209. It is preferable to arrange the openings densely.
  • a third opening is further provided, a flow path connecting the second opening and the third opening is further provided, and a gate mechanism is provided in the flow path so that the medicine supply distribution can be controlled more finely. Is preferred.
  • a plurality of gate mechanisms that open and close by different kinds of energy may be provided in one flow path 209.
  • a gate mechanism that is broken by a shock wave and a gate mechanism that is broken by heat may be provided.
  • the flow path 209 can be opened and closed in multiple stages, and the drug supply distribution can be dynamically changed more finely.
  • the drug is supplied directly to the surface of the internal organ 4 mainly using the sheet-like drug discharge units 201, 250, and 260.
  • a gate mechanism is provided. That is, as shown in FIG. 42, the catheter 270 of this modification 3 is provided with a branch unit 273 in the middle of the tube 2, and a plurality of tubes 271 are connected to the discharge side of the branch unit 273.
  • the medicine injection device 3 side of the branch unit 273 is connected by connectors 274a and 274b.
  • a puncture needle 272 having an opening for discharging a drug is connected to each tip of the plurality of tubes 271.
  • the branch unit 273 is installed on the body surface, and the puncture needles 272 connected through the tubes 271 are punctured into a plurality of internal organs to be treated and distributed.
  • the tubes 271 in the branch unit 273 are branched and connected through a common tube 275, and gate mechanisms 211 and 212 are provided on each tube 271, and on / off of each tube 271 is selectively controlled.
  • the dynamic medicine supply distribution can be easily changed.
  • FIG. 43 is an exploded perspective view showing the configuration of the gate mechanism of Modification 4 of Embodiment 5 of the present invention.
  • FIG. 44 is a diagram showing the operation of the gate mechanism shown in FIG. As shown in FIG. 43, this gate mechanism has a slider housing portion 305a, in which a metal slider 300 having an opening 301 corresponding to the cross section of the flow path 209 is formed on both sides of the flow path 209. It is slidably accommodated in 305b.
  • Slider drive chambers 303a and 303b are provided at the back of the slider accommodating portions 305a and 305b extending from the flow path 209, and magnets 304a and 304b are provided on the walls of the slider drive chambers 303a and 303b on the flow path 209 side, respectively. Is embedded.
  • balloons 302a and 302b are accommodated in the interior chambers separated from the flow path 209 of the slider drive chambers 303a and 303b, respectively.
  • the balloons 302a and 302b are made by covering a fluid such as pure water with an elastic film such as silicon rubber.
  • a fluid such as pure water
  • an elastic film such as silicon rubber.
  • the slider 300 is housed biased toward the slide housing portion 305a.
  • the opening 301 formed in the slider 300 is disposed at a position corresponding to the position of the flow path 209, and the medicine passing through the flow path 209 can freely flow through the opening 301.
  • the slider 300 is in a state in which one end thereof is attracted to the magnet 304b, and is in a stable state in which it does not move unless another force is applied.
  • the balloon 302a is cooled and the volume contracts to return to the original volume of the balloon 302a.
  • the slider 300 moves toward the slider drive chamber 303b by the attractive force of the magnet 304a. Stable when moved.
  • a gate mechanism is provided in the medicine ejection unit 201 as a pad, and the gate mechanism receives energy transmitted from the outside of the medicine ejection unit 201 to flow the medicine in the medicine ejection unit 201. Since the transition is made from one state that is allowed or allowed to the other state that is prohibited or permitted, the dose distribution can be dynamically changed according to the change in the affected area during drug administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention porte sur un cathéter (10) destiné à être fixé à un organe interne d'un mammifère y compris un être humain. Le cathéter (10) comporte un tube (2) qui guide dans le corps un médicament à partir d'une source d'administration de médicament et une section en feuille (1) placée à la pointe du tube (2) et dont la surface arrière adhère au moins partiellement à la surface de l'organe interne. La section en feuille (1) comprend des ouvertures (12) communiquant avec la voie interne du tube (2) et l'aire totale des ouvertures (12) est fixée de manière à être supérieure à l'aire en coupe transversale de la voie interne. Il en résulte qu'on peut administrer le médicament de façon simple et fiable à une zone prédéterminée au voisinage de la surface de l'organe interne.
PCT/JP2009/065749 2008-11-28 2009-09-09 Cathéter WO2010061680A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2008305500A JP2010125227A (ja) 2008-11-28 2008-11-28 カテーテル
JP2008-305500 2008-11-28
JP2008-305501 2008-11-28
JP2008-305499 2008-11-28
JP2008305499A JP2010125226A (ja) 2008-11-28 2008-11-28 カテーテル
JP2008305501A JP2010125228A (ja) 2008-11-28 2008-11-28 カテーテル

Publications (1)

Publication Number Publication Date
WO2010061680A1 true WO2010061680A1 (fr) 2010-06-03

Family

ID=42225560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/065749 WO2010061680A1 (fr) 2008-11-28 2009-09-09 Cathéter

Country Status (1)

Country Link
WO (1) WO2010061680A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012132482A1 (fr) * 2011-03-30 2012-10-04 テルモ株式会社 Feuille adhésive biologique et dispositif pour attacher une feuille adhésive biologique
US9555217B2 (en) 2012-01-31 2017-01-31 Terumo Kabushiki Kaisha Catheter
US10966641B2 (en) 2015-09-04 2021-04-06 Senzime Ab (Publ.) Microdialysis device comprising attachment sheet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02152469A (ja) * 1988-12-02 1990-06-12 Olympus Optical Co Ltd 薬剤カプセル
JP2002529207A (ja) * 1998-11-17 2002-09-10 アンリ・メイエール 活性物質を細胞組織内へと直接的に搬送するためのデバイスおよびこのようなデバイスの埋設手段ならびにデバイス内に活性物質を注入することを意図した器具
US20070156113A1 (en) * 2006-01-03 2007-07-05 Heartcor Organ shealth for percutaneous delivery of biological and pharmacological agents
JP2007534407A (ja) * 2004-04-28 2007-11-29 スミス　アンド　ネフュー　ピーエルシー 創傷を吸引、灌注および／または洗浄する装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02152469A (ja) * 1988-12-02 1990-06-12 Olympus Optical Co Ltd 薬剤カプセル
JP2002529207A (ja) * 1998-11-17 2002-09-10 アンリ・メイエール 活性物質を細胞組織内へと直接的に搬送するためのデバイスおよびこのようなデバイスの埋設手段ならびにデバイス内に活性物質を注入することを意図した器具
JP2007534407A (ja) * 2004-04-28 2007-11-29 スミス　アンド　ネフュー　ピーエルシー 創傷を吸引、灌注および／または洗浄する装置
US20070156113A1 (en) * 2006-01-03 2007-07-05 Heartcor Organ shealth for percutaneous delivery of biological and pharmacological agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012132482A1 (fr) * 2011-03-30 2012-10-04 テルモ株式会社 Feuille adhésive biologique et dispositif pour attacher une feuille adhésive biologique
JPWO2012132482A1 (ja) * 2011-03-30 2014-07-24 テルモ株式会社 生体接着シートおよび生体接着シート貼付デバイス
JP5837050B2 (ja) * 2011-03-30 2015-12-24 テルモ株式会社 生体接着シートおよび生体接着シート貼付デバイス
US9555217B2 (en) 2012-01-31 2017-01-31 Terumo Kabushiki Kaisha Catheter
US10966641B2 (en) 2015-09-04 2021-04-06 Senzime Ab (Publ.) Microdialysis device comprising attachment sheet
US11707212B2 (en) 2015-09-04 2023-07-25 Senzime Ab (Publ.) Microdialysis device comprising attachment sheet

Similar Documents

Publication Publication Date Title
US5282785A (en) Drug delivery apparatus and method
US9547123B2 (en) Systems and methods for treating hollow anatomical structures
ES2369909T3 (es) Artículo absorbente desechable.
JP4722437B2 (ja) 移植可能な薬物送出ポンプおよび弁
JP2002035005A (ja) 治療装置
JPH02307477A (ja) 薬液持続注入器
WO2010061680A1 (fr) Cathéter
PT1133269E (pt) Sistema de libertação controlada para a administração de agêntes terapêuticos no interior do ouvido interno
US11213430B2 (en) Inner ear plug
US20160287380A1 (en) Fluid-filled implantable structures with internal surface-modifying components and related methods
US6726666B2 (en) Inline air humidifier, a system for humidifying air and methods related thereto
JP3586207B2 (ja) ゼリー状体液漏出防止材及びそれを使用した体液漏出防止方法
KR20050122285A (ko) 치료제의 균일 운송을 위한 카테터
JPH0341967A (ja) 薬剤徐放装置
WO2014129551A1 (fr) Moyen à libération contrôlée de liquide de transparence, et endoscope et outil chirurgical endoscopique le comprenant
JP5248556B2 (ja) 薬剤を均等に送達させるためのカテーテル
JPH03218772A (ja) 液体流出量制御部材及びその製造方法
US20220161046A1 (en) Catheter and light irradiation system
WO2014129552A1 (fr) Moyen de libération contrôlée de fluide, et endoscope et instrument chirurgical endoscopique le comprenant
JP2010125228A (ja) カテーテル
JP2010125227A (ja) カテーテル
JP4623796B2 (ja) 体液漏出防止方法
JP2010125226A (ja) カテーテル
KR101839846B1 (ko) 외부 자기장으로 작동이 가능한 생체이식용 약액 펌프
WO2024075723A1 (fr) Dispositif d'administration de médicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828929

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09828929

Country of ref document: EP

Kind code of ref document: A1